{
    "root": "7e66b440-6fcf-4a9d-92a0-33a783384d0c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Atomoxetine"
    },
    "value": "20250502",
    "ingredients": [
        {
            "name": "ATOMOXETINE HYDROCHLORIDE",
            "code": "57WVB6I2W0"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "atomoxetine capsules selective norepinephrine reuptake inhibitor indicated treatment attention-deficit/hyperactivity disorder ( adhd ) . ( 1.1 )",
    "contraindications": "initial , target maximum daily dose ( 2.1 ) ( acute maintenance/extended treatment ) body weight initial daily dose target total daily dose maximum total daily dose children adolescents 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg children adolescents 70 kg adults 40 mg 80 mg 100 mg dosing adjustment — hepatic impairment , strong cyp2d6 inhibitor , patients known cyp2d6 poor metabolizers ( pms ) . ( 2.5 , 12.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "hypersensitivity atomoxetine constituents product . ( 4.1 ) atomoxetine capsules within 2 weeks discontinuing maoi drugs affect brain monoamine concentrations . ( 4.2 , 7.1 ) narrow angle glaucoma . ( 4.3 ) pheochromocytoma history pheochromocytoma . ( 4.4 ) severe cardiovascular disorders might deteriorate clinically important increases hr bp . ( 4.5 )",
    "indications_original": "Atomoxetine capsules are a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1)",
    "contraindications_original": "Initial, Target and Maximum Daily Dose (2.1) (Acute and Maintenance/Extended Treatment) Body Weight Initial Daily Dose Target Total Daily Dose Maximum Total Daily Dose Children and adolescents up to 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg Children and  adolescents over 70 kg and adults 40 mg 80 mg 100 mg Dosing adjustment — Hepatic Impairment, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs). ( 2.5 , 12.3)",
    "adverseReactions_original": "Hypersensitivity to atomoxetine or other constituents of product. (4.1) Atomoxetine capsules use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. (4.2 , 7.1) Narrow Angle Glaucoma. (4.3) Pheochromocytoma or history of pheochromocytoma. (4.4) Severe Cardiovascular Disorders that might deteriorate with clinically important increases in HR and BP. ( 4.5 )"
}